These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33324841)

  • 21. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
    Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
    Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
    Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
    Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against
    Kwon KW; Kang TG; Lee A; Jin SM; Lim YT; Shin SJ; Ha SJ
    Immune Netw; 2023 Apr; 23(2):e16. PubMed ID: 37179749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
    Singh S; Saraav I; Sharma S
    Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
    Nieuwenhuizen NE; Kaufmann SHE
    Front Immunol; 2018; 9():121. PubMed ID: 29459859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.
    Mao L; Xu L; Wang X; Xing Y; Wang J; Zhang Y; Yuan W; Du J; Shi Z; Ma J; Zhang J; Zhang X; Wang X
    Tuberculosis (Edinb); 2022 May; 134():102186. PubMed ID: 35245739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model.
    Rao M; Cadieux N; Fitzpatrick M; Reed S; Arsenian S; Valentini D; Parida S; Dodoo E; Zumla A; Maeurer M
    Int J Infect Dis; 2017 Mar; 56():274-282. PubMed ID: 28161464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Immunogenicity and
    Mao LR; Du JP; Wang XC; Xu LF; Zhang YP; Sun QS; Shi ZL; Xing YR; Su YX; Wang SJ; Wang J; Ma JL; Zhang JY
    ACS Infect Dis; 2023 Mar; 9(3):593-608. PubMed ID: 36808986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.
    Gomez M; Ahmed M; Das S; McCollum J; Mellett L; Swanson R; Gupta A; Carrigy NB; Wang H; Barona D; Bachchhav S; Gerhardt A; Press C; Archer MC; Liang H; Seydoux E; Kramer RM; Kuehl PJ; Vehring R; Khader SA; Fox CB
    Front Pharmacol; 2021; 12():799034. PubMed ID: 35126135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
    Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
    Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell recall response of two hypothetical proteins (Rv2251 and Rv2721c) from Mycobacterium tuberculosis in healthy household contacts of TB - Possible subunit vaccine candidates.
    Santhi D; Raja A
    J Infect; 2016 Nov; 73(5):455-467. PubMed ID: 27404979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycobacterial cell-wall skeleton as a universal vaccine vehicle for antigen conjugation.
    Paik TH; Lee JS; Kim KH; Yang CS; Jo EK; Song CH
    Vaccine; 2010 Nov; 28(50):7873-80. PubMed ID: 20937311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alarmin IL-33 elicits potent TB-specific cell-mediated responses.
    Villarreal DO; Siefert RJ; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1954-60. PubMed ID: 26091147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugation with an Inulin-Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein.
    Yu W; Hu T
    Mol Pharm; 2016 Nov; 13(11):3626-3635. PubMed ID: 27723352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
    Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
    Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.